|
CLCN2 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.47419989946241E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
3.26430005248568E-09 |
| Normal-vs-Stage2 |
5.022500E-03 |
| Normal-vs-Stage3 |
3.38920003173371E-09 |
| Normal-vs-Stage4 |
5.87379999972271E-07 |
| Stage1-vs-Stage2 |
2.438200E-01 |
| Stage1-vs-Stage3 |
2.038600E-01 |
| Stage1-vs-Stage4 |
4.931000E-01 |
| Stage2-vs-Stage3 |
7.504400E-02 |
| Stage2-vs-Stage4 |
1.382620E-01 |
| Stage3-vs-Stage4 |
7.883800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
9.30870047710641E-10 |
| Normal-vs-AfricanAmerican |
2.864200E-03 |
| Normal-vs-Asian |
5.033600E-04 |
| Caucasian-vs-AfricanAmerican |
5.452600E-01 |
| Caucasian-vs-Asian |
2.480400E-01 |
| AfricanAmerican-vs-Asian |
8.267000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
3.85970000005287E-06 |
| Normal-vs-Female |
1.2191003762041E-10 |
| Male-vs-Female |
1.472570E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
8.92700025012516E-10 |
| Normal-vs-Age(41-60Yrs) |
8.23010004591396E-09 |
| Normal-vs-Age(61-80Yrs) |
9.59779999999411E-05 |
| Normal-vs-Age(81-100Yrs) |
2.19899999998052E-06 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.791800E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
2.304400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.657400E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.136600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
2.789000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.943900E-02 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.900100E-03 |
| Classical-VS-Follicular |
5.738400E-01 |
| Classical-VS-Other |
4.078800E-01 |
| Classical-VS-Normal |
2.21560003677013E-09 |
| Tall-VS-Follicular |
1.094480E-02 |
| Tall-VS-Other |
2.296300E-02 |
| Tall-VS-Normal |
1.77750003604871E-09 |
| Follicular-VS-Other |
6.413400E-01 |
| Follicular-VS-Normal |
1.396420E-04 |
| Other-VS-Normal |
1.596590E-01 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.2835999999572E-06 |
| Normal-vs-N1 |
5.14310000032658E-07 |
| N0-vs-N1 |
2.364000E-01 |
|
|
